$68.26
+0.73 (+1.08%)
Performance
1D
—
1W
—
1M
—
3M
-7.18%
6M
-18.33%
1Y
+54.29%
YTD
-13.69%
Open$67.65
Previous Close$67.53
Day High$70.30
Day Low$67.37
52W High$99.50
52W Low$40.00
Volume—
Avg Volume385.6K
Market Cap2.58B
P/E Ratio—
EPS$-5.98
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$78.91
Below
SMA 200
$68.08
Above
RSI (14)
34.9
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
19 analysts
Price Target
-67.1% upside
Current
$68.26
$68.26
Target
$22.47
$22.47
$15.33
$22.47 avg
$35.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.46B | 1.47B | 1.18B |
| Net Income | -261,677,643 | -297,076,371 | -250,070,353 |
| Profit Margin | -18.0% | -20.2% | -21.1% |
| EBITDA | -537,620,569 | -578,764,523 | -403,482,661 |
| Free Cash Flow | -321,004,356 | -279,609,663 | -183,137,834 |
| Rev Growth | +12.9% | +6.2% | -8.5% |
| Debt/Equity | 0.11 | 0.12 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |